VIRGINIA RETIREMENT SYSTEMS ET Al Acquires New Holdings in Krystal Biotech, Inc. $KRYS

VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in Krystal Biotech, Inc. (NASDAQ:KRYS) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 10,400 shares of the company’s stock, valued at approximately $3,865,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of KRYS. Royal Bank of Canada increased its stake in Krystal Biotech by 145.2% during the 1st quarter. Royal Bank of Canada now owns 1,628 shares of the company’s stock valued at $294,000 after buying an additional 964 shares during the period. AQR Capital Management LLC boosted its holdings in shares of Krystal Biotech by 29.9% in the first quarter. AQR Capital Management LLC now owns 12,131 shares of the company’s stock valued at $2,187,000 after acquiring an additional 2,792 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Krystal Biotech by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,893 shares of the company’s stock valued at $2,870,000 after acquiring an additional 688 shares in the last quarter. Empowered Funds LLC acquired a new position in shares of Krystal Biotech during the first quarter valued at approximately $218,000. Finally, Cetera Investment Advisers increased its stake in shares of Krystal Biotech by 107.9% during the second quarter. Cetera Investment Advisers now owns 4,344 shares of the company’s stock valued at $597,000 after acquiring an additional 2,255 shares during the period. Institutional investors own 86.29% of the company’s stock.

Krystal Biotech Stock Performance

Shares of NASDAQ:KRYS opened at $348.09 on Thursday. The stock has a market capitalization of $10.30 billion, a price-to-earnings ratio of 43.62 and a beta of 0.54. Krystal Biotech, Inc. has a 1-year low of $136.73 and a 1-year high of $382.54. The company has a 50 day moving average price of $348.54 and a 200 day moving average price of $309.17.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings results on Monday, August 3rd. The company reported $1.79 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.70 by $0.09. Krystal Biotech had a net margin of 54.82% and a return on equity of 19.34%. The firm had revenue of $119.22 million for the quarter, compared to analyst estimates of $120.93 million. On average, sell-side analysts expect that Krystal Biotech, Inc. will post 7.48 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently commented on the company. Royal Bank Of Canada assumed coverage on Krystal Biotech in a report on Friday, August 14th. They set an “outperform” rating and a $400.00 target price on the stock. TD Cowen increased their price target on Krystal Biotech from $306.00 to $403.00 and gave the company a “buy” rating in a research note on Thursday, June 18th. Wall Street Zen cut Krystal Biotech from a “buy” rating to a “hold” rating in a research report on Saturday, June 20th. Bank of America boosted their price objective on Krystal Biotech from $364.00 to $396.00 and gave the stock a “buy” rating in a research note on Tuesday, July 14th. Finally, Citigroup upped their price objective on Krystal Biotech from $378.00 to $386.00 and gave the company a “buy” rating in a report on Tuesday, August 4th. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat, Krystal Biotech has a consensus rating of “Moderate Buy” and a consensus price target of $365.40.

Insider Buying and Selling

In other news, EVP John Thomas sold 1,000 shares of the company’s stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $347.27, for a total transaction of $347,270.00. Following the completion of the sale, the executive vice president directly owned 1,000 shares of the company’s stock, valued at $347,270. This represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Dino A. Rossi sold 25,000 shares of the stock in a transaction on Friday, August 14th. The shares were sold at an average price of $329.12, for a total value of $8,228,000.00. Following the completion of the transaction, the director owned 50,000 shares of the company’s stock, valued at $16,456,000. This trade represents a 33.33% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 51,000 shares of company stock worth $17,558,270 in the last three months. 13.10% of the stock is currently owned by insiders.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.